PedAM
Pediatric Disease Annotations & Medicines
| zollinger-ellison syndrome | ||||
| Disease ID | 891 |
|---|---|
| Disease | zollinger-ellison syndrome |
| Definition | A syndrome that is characterized by the triad of severe PEPTIC ULCER, hypersecretion of GASTRIC ACID, and GASTRIN-producing tumors of the PANCREAS or other tissue (GASTRINOMA). This syndrome may be sporadic or be associated with MULTIPLE ENDOCRINE NEOPLASIA TYPE 1. |
| Synonym | ellison syndrome zollinger excessive gastrin secretion gastrinoma syndrome pancreatic ulcerogenic tumor syndrome syndrome gastrinoma syndrome z-e syndrome zollinger ellison syndrome zollinger ellisons syndrome zollinger-ellison syndrome, zollinger-ellison ulcerogenic tumor of the pancreas syndrome z-e syndrome ze - zollinger-ellison syndrome zollinger - ellison syndrome zollinger ellison syndrome zollinger-ellison syndr zollinger-ellison syndrome (disorder) zollinger-ellison syndrome [disease/finding] |
| Orphanet | |
| DOID | |
| UMLS | C0043515 |
| MeSH | |
| SNOMED-CT | |
| Comorbidity | UMLS | Disease | Sentences' Count(Total Sentences:9) C0017150 | gastrinoma | 1 C0020459 | hyperinsulinemia | 1 C0027662 | multiple endocrine neoplasia | 1 C0030920 | peptic ulcer | 1 C0017152 | gastritis | 1 C0017155 | hypertrophic gastropathy | 1 C0017154 | atrophic gastritis | 1 C0011991 | diarrhoea | 1 C1333321 | duodenal gastrinoma | 1 |
| Curated Gene | (Waiting for update.) |
| Inferring Gene | (Waiting for update.) |
| Text Mined Gene | Entrez_id | Symbol | Score | Resource(Total Genes:49) 6343 | SCT | DISEASES 1113 | CHGA | DISEASES 479 | ATP12A | DISEASES 5539 | PPY | DISEASES 2026 | ENO2 | DISEASES 2691 | GHRH | DISEASES 4201 | MEA1 | DISEASES 3630 | INS | DISEASES 4922 | NTS | DISEASES 2922 | GRP | DISEASES 2694 | GIF | DISEASES 495 | ATP4A | DISEASES 6855 | SYP | DISEASES 23476 | BRD4 | DISEASES 5775 | PTPN4 | DISEASES 5443 | POMC | DISEASES 3067 | HDC | DISEASES 9616 | RNF7 | DISEASES 6570 | SLC18A1 | DISEASES 5741 | PTH | DISEASES 6750 | SST | DISEASES 6571 | SLC18A2 | DISEASES 10022 | INSL5 | DISEASES 56776 | FMN2 | DISEASES 2520 | GAST | DISEASES 796 | CALCA | DISEASES 885 | CCK | DISEASES 4221 | MEN1 | DISEASES 56477 | CCL28 | DISEASES 259230 | SGMS1 | DISEASES 7432 | VIP | DISEASES 1081 | CGA | DISEASES 9077 | DIRAS3 | DISEASES 1557 | CYP2C19 | DISEASES 5225 | PGC | DISEASES 253430 | IPMK | DISEASES 5089 | PBX2 | DISEASES 3274 | HRH2 | DISEASES 1114 | CHGB | DISEASES 293 | SLC25A6 | DISEASES 2618 | GART | DISEASES 60312 | AFAP1 | DISEASES 4828 | NMB | DISEASES 2641 | GCG | DISEASES 4295 | MLN | DISEASES 10640 | EXOC5 | DISEASES 26013 | L3MBTL1 | DISEASES 131 | ADH7 | DISEASES 4850 | CNOT4 | DISEASES |
| Locus | (Waiting for update.) |
| Disease ID | 891 |
|---|---|
| Disease | zollinger-ellison syndrome |
| Integrated Phenotype | HPO | Name(Total Integrated Phenotypes:34) HP:0100633 | Esophagitis HP:0001578 | Hypercortisolism HP:0000845 | Growth hormone excess HP:0002239 | Gastrointestinal hemorrhage HP:0002044 | Zollinger-Ellison syndrome HP:0001824 | Weight loss HP:0008256 | Adrenocortical adenoma HP:0000952 | Jaundice HP:0011761 | Pituitary null cell adenoma HP:0002014 | Diarrhea HP:0002588 | Duodenal ulcer HP:0003165 | Elevated circulating parathyroid hormone level HP:0002573 | Hematochezia HP:0012030 | Increased urinary cortisol level HP:0012032 | Lipoma HP:0008291 | Pituitary corticotropic cell adenoma HP:0001012 | Multiple lipomas HP:0008208 | Parathyroid hyperplasia HP:0030404 | Glucagonoma HP:0002018 | Nausea HP:0000854 | Thyroid adenoma HP:0100634 | Neuroendocrine neoplasm HP:0005214 | Intestinal obstruction HP:0002574 | Episodic abdominal pain HP:0012334 | Extrahepatic cholestasis HP:0002893 | Pituitary adenoma HP:0003072 | Hypercalcemia HP:0011760 | Pituitary growth hormone cell adenoma HP:0030688 | Increased glucagon level HP:0006744 | Adrenocortical carcinoma HP:0000843 | Hyperparathyroidism HP:0004398 | Peptic ulcer HP:0006767 | Pituitary prolactin cell adenoma HP:0010783 | Erythema |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:8) HP:0002664 | Neoplasia | 4 HP:0100568 | Endocrine neoplasia | 1 HP:0002027 | Abdominal pain | 1 HP:0012531 | Pain | 1 HP:0030404 | Glucagonoma | 1 HP:0005263 | Gastritis | 1 HP:0004398 | Peptic ulcer | 1 HP:0000842 | Elevated insulin level | 1 |
| Disease ID | 891 |
|---|---|
| Disease | zollinger-ellison syndrome |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:3) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:3) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0043515 | cimetidine | D002927 | 51481-61-9 | zollinger-ellison syndrome | MESH:D015043 | therapeutic | 375397 | ||
| C0043515 | omeprazole | D009853 | 73590-58-6 | zollinger-ellison syndrome | MESH:D015043 | therapeutic | 1392958 | ||
| C0043515 | pantoprazole | C064276 | 102625-70-7 | zollinger-ellison syndrome | MESH:D015043 | therapeutic | 11774936 | ||
FDA approved drug and dosage information(Total Drugs:4) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D015043 | prilosec | omeprazole | 20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | CAPSULE, DELAYED REL PELLETS;ORAL | Discontinued | None | Yes | No |
| MESH:D015043 | prilosec | omeprazole | 20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | CAPSULE, DELAYED REL PELLETS;ORAL | Discontinued | None | Yes | No |
| MESH:D015043 | omeprazole | omeprazole | 20MG | TABLET, DELAYED RELEASE;ORAL | Over-the-counter | None | Yes | Yes |
| MESH:D015043 | omeprazole | omeprazole | 20MG | TABLET, DELAYED RELEASE;ORAL | Over-the-counter | None | Yes | Yes |
FDA labeling changes(Total Drugs:4) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D015043 | 12/7/2002 | prilosec | omeprazole | Gastroesophageal reflux and erosive esophagitis | Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile | Labeling | B | - | - | - | AstraZeneca | - | FALSE' |
| MESH:D015043 | 03/20/2008 | prilosec | omeprazole | Maintenance healing of erosive esophagitis | Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form | Labeling | - | - | B, P | - | AstraZeneca | 1/5/2001 | FALSE' |
| MESH:D015043 | 12/7/2002 | prilosec | omeprazole | Gastroesophageal reflux and erosive esophagitis | Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile | Labeling | B | - | - | - | AstraZeneca | - | FALSE' |
| MESH:D015043 | 03/20/2008 | prilosec | omeprazole | Maintenance healing of erosive esophagitis | Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form | Labeling | - | - | B, P | - | AstraZeneca | 1/5/2001 | FALSE' |